Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

AMAG Pharmaceuticals, Inc. today provided an update on the commercial launch of Feraheme® (ferumoxytol) Injection for intravenous (IV) use, including preliminary fourth quarter 2009 Feraheme net product revenues estimates, as well as an update on the Company’s international and label expansion efforts.

10 Jan 2010

3Sbio submits registrational clinical trial application for Feraheme injection

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a registrational clinical trial to the Chinese State Food and Drug Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous use.

8 Jan 2010

RMEI and PIM sponsor medical education virtual lecture for physicians on HAE management

Hereditary angioedema (HAE) is a disease affecting between 4,000 and 10,000 people in the United States each year, causing recurrent attacks of intense localized edema. HAE can be both difficult to diagnose and difficult to treat.

7 Jan 2010

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it has initiated its Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 in patients undergoing cataract surgery.

6 Jan 2010

DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that the independent Data Safety Monitoring Board ("DSMB") recommended that QPI-1002 (I5NP) continue on to the next phase of clinical testing.

5 Jan 2010

VELCADE sNDA receives FDA approval

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

5 Jan 2010

iCo Therapeutics grants 725,000 stock options to directors, officers and employees

iCo Therapeutics Inc. - iCo Therapeutics (the "Company") announced today that on December 29, 2009 the Company granted a total of 725,000 stock options to directors, officers and employees of the Company.

31 Dec 2009

Remedies to alleviate foot pain during pregnancy

"Oh my aching feet" is a phrase you hear often from pregnant women. But are sore feet a symptom they just must deal with during pregnancy? According to the American College of Foot and Ankle Surgeons (ACFAS) the answer is "no." There are many remedies available to help alleviate foot pain.

30 Dec 2009

Steroids not superior to laser treatments for DME

Researchers led by specialists at the Johns Hopkins Wilmer Eye Institute have found that injecting a corticosteroid, triamcinolone, directly into the eye may slow the progression of proliferative diabetic retinopathy, a complication of diabetes that frequently leads to blindness.

27 Dec 2009

Positive results from Alimera Sciences' Iluvien FAME trial for DME

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported top-line results from the month 24 readout of the FAME Study.

23 Dec 2009

Researchers recommend progesterone as viable treatment for traumatic brain injuries

Researchers at Emory University in Atlanta, GA, recommend that progesterone (PROG), a naturally occurring hormone found in both males and females that can protect damaged cells in the central and peripheral nervous systems, be considered a viable treatment option for traumatic brain injuries, according to a clinical perspective published in the January issue of the American Journal of Roentgenology.

23 Dec 2009

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Celgene Corporation today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB).

18 Dec 2009

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced top-line efficacy and safety results from a Phase 2b clinical trial of XIAFLEX(TM) for the treatment of Peyronie's disease.

17 Dec 2009

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced top-line efficacy and safety results for the phase IIb clinical trial for XIAFLEX™ (collagenase clostridium histolyticum) in the treatment of Peyronie's disease.

16 Dec 2009

ThromboGenics completes enrollment in second microplasmin Phase III trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

16 Dec 2009

Physicians need to utilize best practices to treat HAE patients in emergency settings

Hereditary Angioedema (HAE) is an autosomal dominant disease causing acute attacks of intense edema. These attacks can result in life-threatening complications, including asphyxiation.

16 Dec 2009

PPI announces new Exotec Cubital Tunnel Splint

When staff from a leading orthopaedic group grew tired of struggling to apply the difficult to adjust and uncomfortable cubital tunnel splints available on the market, they enlisted Professional Products, Inc. (PPI) to develop a superior alternative. PPI, a leader and innovator in orthopaedic solutions for nearly five decades, responded with the revolutionary Exotec Cubital Tunnel Splint(TM) (cubitaltunnelsplint.com), which it announced today.

15 Dec 2009

Phase 1 clinical trial of iCo-007 demonstrates positive safety profile

iCo Therapeutics Inc. - iCo Therapeutics ("iCo") is pleased to announce that its Phase 1 clinical trial of iCo-007, having enrolled all patients in four cohorts of increasing concentration (110ug, 350ug, 700ug, 1000ug), has to date demonstrated a positive safety profile.

12 Dec 2009

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

Edema News and Research

Further Reading

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

3Sbio submits registrational clinical trial application for Feraheme injection

RMEI and PIM sponsor medical education virtual lecture for physicians on HAE management

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002

VELCADE sNDA receives FDA approval

iCo Therapeutics grants 725,000 stock options to directors, officers and employees

Remedies to alleviate foot pain during pregnancy

Steroids not superior to laser treatments for DME

Positive results from Alimera Sciences' Iluvien FAME trial for DME

Researchers recommend progesterone as viable treatment for traumatic brain injuries

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

ThromboGenics completes enrollment in second microplasmin Phase III trial

Physicians need to utilize best practices to treat HAE patients in emergency settings

PPI announces new Exotec Cubital Tunnel Splint

Phase 1 clinical trial of iCo-007 demonstrates positive safety profile

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News